Kidney Cancer

CURE spoke with Alyson B. Moadel-Robblee of Montefiore Einstein Center for Cancer Care.

Patients with advanced renal cell carcinoma whose disease has progressed on first-line therapies may benefit from the combination of Fruzaqla and Tyvyt.

Dr. Ravi Munver discusses how minimally invasive techniques allow patients to preserve kidney function and practical guidance for navigating treatment.

Dr. Ravi Munver highlights how minimally invasive treatment has improved recovery and quality, improving outcomes for patients with kidney cancer

Remote monitoring has been found to be associated with improved postsurgical recovery for patients with cancer.

As September concludes, the landscape of GU oncology continues to evolve, with important developments in prostate, bladder, kidney and other cancers.

This guide on stage 2 kidney cancer covers key info, treatments and what to expect, helping you prepare for informed discussions with your care team.

Molecular testing helps distinguish kidney cancer subtypes, ensuring patients get accurate diagnoses and treatment plans, avoiding unnecessary surgery.

Dr. Ravi Munver sat down for an interview with CURE to discuss progress in kidney cancer care.

I reflect on how my family and friends showed love in different ways during the early days of my chronic cancer diagnosis.

Researchers have created a novel immunotherapy for metastatic kidney cancer that could provide a new treatment option for patients with limited options.

Early-stage kidney cancer is limited to the kidney, usually under seven centimeters and often has a very good prognosis when treated promptly.

Kristen Dahlgren of the Cancer Vaccine Coalition spoke with CURE about why she remains hopeful for the future or cancer vaccines.

A dual cancer diagnosis rewired how I live, love, and show up in the world — with presence, purpose, and unapologetic passion.

Fotivda preserved quality-of-life scores in kidney cancer, with better outcomes in second-line use and no added benefit from combining with Opdivo.

PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.

Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.

Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of life, not just disease control.

Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.

Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.

Early data suggest personalized neoantigen vaccines activate the immune system and sustain tumor control in some patients with kidney cancer.

June brought genitourinary cancer updates, and CURE is sharing the latest in kidney cancer treatment, as well as FDA approvals, cancer vaccines and more.

Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.